ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed December 06 4:00PM
Realtime Data

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
42.20
Bid
41.80
Ask
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
Zorax Zorax 1 minute ago
Well, just based on my limited experiences and readings. Did you have a decent relationship with your Father? Or at least kind of a normal one?

If mush's son had something so strong inside him he struggled with and went to his Dad, who he believed he can talk to and seek help tell him
knrorrel knrorrel 1 minute ago
watch $FORW and $GVSI (yesterday was just a taste / day one of how quickly and what could happen to these stocks, next week and especially in 2025 , when news comes-Both stocks have been beaten down, SS is good, now everything is back to square one and the potential is immeasurable, imho ὒ
FORW GVSI
DMC8 DMC8 2 minutes ago
06 December 2024
https://link.springer.com/article/10.1186/s12937-024-01051-y
AMRN
knrorrel knrorrel 2 minutes ago
$SMCI MONDAY HOLY SHI_

SMCI
ccie1024 ccie1024 3 minutes ago
Non-motion response posted to courtlistener…
NWBO
PonderosaPack PonderosaPack 3 minutes ago
Good Job Jack - congrats for the foresight. I was in late around $5-6 - but recently got busy in past 6 months. Hats off to you for the long haul. I saw something 12 years ago about Quantum - so I had my eye on it. You got in way before me and I'm sure that first 3 years was brutal. so hats
IONQ
knrorrel knrorrel 3 minutes ago
watch $FORW and $GVSI (yesterday was just a taste / day one of how quickly and what could happen to these stocks, next week and especially in 2025 , when news comes-Both stocks have been beaten down, SS is good, now everything is back to square one and the potential is immeasurable, imho ὒ
FORW GVSI
pinkslipjunkie pinkslipjunkie 4 minutes ago
They delivered like your email said...a day late...but hey... we won't hold that against them...now the reason for the changes in the unrestricted shares and increasing the Outstanding shares...we might...LOL
AFFU
yp_1 yp_1 4 minutes ago
So far Fortuna has been turning away and showing us her bum.
SEV
ron_66271 ron_66271 5 minutes ago
4364, 4362; “Federal National Mortgage Association, The Federal Deposit Insurance Corporation as Receiver,”

FMCC is also in the filings.
RESOLUTION.



Ron
FMCC
Steady_T Steady_T 6 minutes ago
I'll take a different position on that. I don't think that Missling will wait for the EMA to make a decision on approval before filing the NDA.

My reasoning is this. The time delay on EMA making a decision will be between 6 month, if they get AA, to 460 days or so.

That
AVXL
vg_future vg_future 6 minutes ago
on 11/19/24 - options exercised for 10.09 when the stock closed around 8.25.....that shows confidence. Also, another piece of info (maybe I missed it earlier)...the MAA was filed/submitted on 11/19/2024 triggering the vesting of the options. From Missling's FORM 4

Explanation of Resp
AVXL
LTListener LTListener 8 minutes ago
Bread crumbs generally are small
RSPI
mike_dotcom mike_dotcom 8 minutes ago
The options were vested - not exercised.
AVXL
LTListener LTListener 8 minutes ago
Oh yeah I guess you just need to be granted professional or sophisticated status to trade bread crumbs…
RSPI
trademax42 trademax42 9 minutes ago
Nice!! Good to see you in the house Hercules1!!
HMBL
MrSmith101 MrSmith101 9 minutes ago
No one is buying this garbage. Ethema will last as long as Leon and his wife want to keep bankrolling it. It’s really that simple.
GRST
EarningsCentral EarningsCentral 10 minutes ago
SWBI
MrSmith101 MrSmith101 11 minutes ago
Ok you realize how insane what you just wrote is right? They have 82 beds right now officially. You cant just say 3,000 beds as if thats true.
GRST
familyof5 familyof5 11 minutes ago
It has to do with OTCN and dilution https://otce.finra.org/otce/marketStatistics/monthlyShareVolume
AFFU
catdaddy catdaddy 12 minutes ago
" On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included completion of the Clinical Study Report for Phase 2a/b AD-004 Alzheimer's disease study. The
AVXL
RKMKE RKMKE 12 minutes ago


Here are the screenshot if anyone wanted to read
WDLF
knrorrel knrorrel 13 minutes ago
You were absolutely right, yesterday was day one and the increase can continue next week
imho

FORW

Your Recent History

Delayed Upgrade Clock